Radioguided occult lesion localization (ROLL) and excision of breast lesions using technetium-99m-macroaggregate albumin and air injection control.

The aim of this study was to assess the efficiency of the radioguided localization and excision technique using radiopharmaceuticals injected directly or close to occult breast lesions. We studied thirty-two consecutive patients with thirty-six occult breast lesions detected mammographically or ultrasonically categorized as BI-RADS 3, 4 or 5. Macroaggregate Albumin (MAA) labeled with (99m)Tc was administered directly or close to the lesion, guided by mammography or ultrasound, followed by an air injection for radiological control. The excision biopsy was carried out with the aid of a hand-held gamma detecting probe and the entire removal of the lesion was verified by X-ray of the surgical specimens or by intraoperatory frozen section examination. Breast cancer was found in 8.3% of BI-RADS 3 lesions, in 33.3% of the BI-RADS 4 lesions and in 66.6% of the BI-RADS 5 lesions. The radiotracer was correctly positioned in 97.2% of the specimens (35/36) allowing the removal of 97.2%. Xray confirmed the entire removal in 27 lesions (75%), intraoperatory frozen section study in 19.4% (7/36) and by both methods in 5.5% (2/36). Radioguided surgery turned out to be an important tool in the removal of non-palpable breast lesions, as a simple, fast and feasible method that can be implemented in the clinical routine of patients with non-palpable breast lesions.

Identification of sentinel node in breast cancer: comparison between peritumoral and periareolar injection of the radiopharmaceutical contrast medium.

Axillary node status is the most important prognostic factor for patients with primary breast carcinoma. The sentinel node biopsy (SN) technique has received much attention as a possible alternative to axillary lymph node dissection. The aim of this study is to identify the sentinel node by periareolar and subdermal injection of the radiopharmaceutical in four points, independent of tumor topography and the presence of biopsies and/or previous surgery. The peritumoral injection technique was carried out for comparison purposes. This study was performed on 115 patients, divided into 2 groups: Group A (25 patients, peritumoral injection) and Group B (90 patients, injection in four points). All the SN biopsies were studied by both imprint cytology and H&E staining. Control axillary lymph-node dissection was followed in all patients from Group A and in these positive cases from Group B. Twenty-two out of the twenty-five (88%) SNs were identified in Group A. There was no false negative; the sensitivity and specificity were 100%. Eighty-two of the ninety (91.1%) SNs were identified in Group B. Lymphoscintigraphy showed radiopharmaceutical migration to axilla in 93.7% of the cases. Hotspot area was 10 to 100 times the intensity of the background radiation. Among the 92 cases with negative sentinel nodes at intraoperative examination (TP), the SN histopathology confirmed the absence of cancer cells in 89 patients, whereas 3 were positive for metastatic cells. This study shows that periareolar injection in four points seems to be a good lymphatic mapping method for SN identification. We suggest standardizing this site of injection to identify the SNs. More studies to confirm these findings are ongoing.